NASDAQ:LQDA Liquidia Q1 2025 Earnings Report $15.83 +1.85 (+13.23%) Closing price 04:00 PM EasternExtended Trading$15.86 +0.03 (+0.19%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast Liquidia EPS ResultsActual EPSN/AConsensus EPS -$0.42Beat/MissN/AOne Year Ago EPSN/ALiquidia Revenue ResultsActual RevenueN/AExpected Revenue$3.23 millionBeat/MissN/AYoY Revenue GrowthN/ALiquidia Announcement DetailsQuarterQ1 2025Date5/12/2025TimeBefore Market OpensConference Call DateTuesday, May 13, 2025Conference Call Time8:30AM ETConference Call ResourcesEarnings HistoryCompany Profile Liquidia Earnings HeadlinesDistrict Court Dismisses Dispute Filed by United Therapeutics Against LiquidiaMay 2 at 5:28 PM | globenewswire.comLiquidia Corporation to Report First Quarter 2025 Financial Results on May 8, 2025May 1 at 8:00 AM | globenewswire.comTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.May 2, 2025 | Porter & Company (Ad)Scotiabank Sticks to Their Buy Rating for Liquidia Technologies (LQDA)April 24, 2025 | markets.businessinsider.comLiquidia Corp files patent infringement suit against United TherapeuticsApril 24, 2025 | uk.investing.comLiquidia Co. (NASDAQ:LQDA) Receives $26.63 Consensus PT from AnalystsApril 24, 2025 | americanbankingnews.comSee More Liquidia Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Liquidia? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Liquidia and other key companies, straight to your email. Email Address About LiquidiaLiquidia (NASDAQ:LQDA), a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.View Liquidia ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Amazon Earnings: 2 Reasons to Love It, 1 Reason to Be CautiousMeta Takes A Bow With Q1 Earnings - Watch For Tariff Impact in Q2Palantir Earnings: 1 Bullish Signal and 1 Area of ConcernMicrosoft Crushes Earnings, What’s Next for MSFT Stock?Qualcomm's Earnings: 2 Reasons to Buy, 1 to Stay AwayAMD Stock Signals Strong Buy Ahead of EarningsAmazon's Earnings Will Make or Break the Stock's Comeback Upcoming Earnings Palantir Technologies (5/5/2025)Vertex Pharmaceuticals (5/5/2025)CRH (5/5/2025)Realty Income (5/5/2025)Williams Companies (5/5/2025)American Electric Power (5/6/2025)Advanced Micro Devices (5/6/2025)Marriott International (5/6/2025)Constellation Energy (5/6/2025)Arista Networks (5/6/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
